May 6, 2009 (FinancialWire) — ICON plc (NASDAQ: ICLR) (ISIN: IE0005711209) has acquired a 33,000-square-foot Phase I facility in Omaha, Nebraska, with a capacity of up to 100 beds, formerly owned by Qualia Clinical Services, Inc.

ICON has also announced the appointment of Dr. Gary Curtis as senior VP, global clinical pharmacology. He will integrate the Omaha facility with ICON’s existing Phase I units and will be supported by key clinical operational staff from Qualia who have been rehired by ICON.

The acquisition brings ICON’s total bed capacity in Phase I facilities in the U.S. to approximately 225 beds, according to Dr.Thomas Frey, president, ICON development solutions.

Curtis spent nearly 20 years with MDS Pharma Services where he was responsible for operational execution, strategic growth, and integration of MDS’ global early phase business units.

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.